A Case of Favorable Responses after Gefitinib in a Patient with EGFR Mutated Adenosquamous Lung Carcinoma.
- Author:
Nam Jun CHO
1
;
Ho Sung LEE
;
Si Hyong JANG
;
Jae Sung CHOI
;
Ju Ock NA
;
Ki Hyun SEO
;
Yong Hoon KIM
;
Hyo Chul KANG
;
Dae Yeon KIM
Author Information
1. Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea. c78172@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Adenosquamous carcinoma;
Epidermal growth factor receptor;
Mutation;
Non-small-cell lung carcinoma
- MeSH:
Carcinoma, Adenosquamous;
Carcinoma, Non-Small-Cell Lung;
Epidermal Growth Factor;
Humans;
Lung*;
Phosphotransferases;
Receptor, Epidermal Growth Factor
- From:Soonchunhyang Medical Science
2013;19(2):123-127
- CountryRepublic of Korea
- Language:English
-
Abstract:
In patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as first treatment option. Because adenosquamous carcinoma (ASC) is a rare histologic subtype, evidences about EGFR-TKIs as first treatment option for advanced ASC are lacking. We report a case of an advanced ASC patient with the EGFR mutation, who showed good responses during 4-month treatment with gefitinib. And we will review about a necessity of EGFR mutation test and efficacy of EGFR-TKIs in ASC patients from the recent studies.
